基本信息
浏览量:24
职业迁徙
个人简介
After a PhD in Organic Chemistry (University of Louvain, Belgium) and two post docs in the fields of organic and biological chemistry (UC Irvine and MIT, US), I started my professional career at Roussel Uclaf in January 1987 as an organic chemist where I moved my way from head of laboratory to Project Leader and head of exploratory research in the Endocrinology Department. From this research, we delivered potent aromatase inhibitors (RU's outlicensing portfolio), estrogen receptor antagonists (for hormone-dependent breast cancer) and inhibitors of the enzyme 5-α-reductase. This work also gave rise to 8 publications (7 as first author) and 9 patents.
In 1994 the endocrinology department was turned into a bone disease therapeutic area. In this context, I became the project leader of a high visibility multicentric project dealing with the search for inhibitors of the Src protein. This 42 M$ collaboration with an American pharmaceutical company, ARIAD Pharmaceuticals was dealing with protein-protein interactions through inhibition of SH2 and SH3 protein domains and was pursued with large teams of scientists in France (30), Boston (20) along with Tucson and Frankfurt. This project gave rise to the first SAR by XRay ever reported (after the seminal article of Fesik on SAR by NMR) and also the first fragment approach performed in our company. The project was terminated at the merger with Rhone Poulenc and all assets left with ARIAD. This work gave rise to 13 publications (4 as first author), 11 patents and several presentations at international symposia.
In 1998 I became co-Head of the Medicinal Chemistry Department of Hoechst Marion Roussel and have been head of medicinal chemistry departments or sections throughout the next organizations in Aventis (section head in Med Chem), Sanofi-Aventis (head of CNS Med Chem Vitry) and Sanofi (head of the medicinal chemistry in the TSU Aging) until 2014. These functions, either in therapeutic area or in platforms, encompassed scientific supervision of all medicinal chemistry projects and direct management of 30-50 scientists, along with coordination of teams in Frankfurt, Bridgewater and Tucson. During these days I was also direct project leader for two high priority projects, both of them worked with chemistry in Vitry, Frankfurt and Tucson (GSK3 beta inhibitors and IGF1R inhibitors). These 2 projects led to candidates, 4 publications as first author and 10 patents. Altogether in my medicinal chemistry perimeter 13 candidates were proposed to development in the fields of Oncology, Neurodegeneration, Antiinfectives and Bone Diseases. One of these, a beta-lactamase inhibitor Avibactam (further developed at Novexel, then Astra Zeneca), is now on the market.
During the last 15 years, owing to the growing importance of biotherapeutics in the pharmaceutical world I became increasingly interested in blood brain barrier crossing in particular by biologics. This led to initiation of internal projects on siRNA’s and antibodies brain delivery and to several external collaborations in the field along with participation to IMIs (IMI COMPACT as leader of the blood brain barrier package and more recently as scientific leader of the IMI IM2PACT on BBB). In 2016 I was recruited in the Neurosciences therapeutic area to create a group on CNS barriers. This work led to the establishment of a robust platform for tissue enhancement of biologics based on internally discovered mAbs and nanobodies. In addition , this group also devised several strategies towards the discovery of new neurovascular targets for brain delivery and therapeutics. The function was extended to head of Tissue barriers. This new part of my career was a substantial change as I went from directing medicinal chemists to biologists and pharmacologists. This has only been possible through the acquisition of solid bases in biology, biotherapeutics and pharmacology.
Since February 2023, I am consulting on medicinal chemistry and blood brain barrier crossing of biotherapeutics (BBB/MedChem Consulting).
I have written more than 65 articles, patents, reviews and book chapters and am a recognized expert in both the fields of organic and medicinal chemistry (former Vice President of the French Therapeutic Chemistry Society, member of the Doctoral School MCTI Paris, expert in several French governmental commissions, universities and European Consortia and also an active reviewer for peer-reviewed journals and jury of several PhD theses.
研究兴趣
论文共 85 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Magdalena Kurtyka,Frank Wessely, Sarah Bau, Eseoghene Ifie,Liqun He,Nienke M. de Wit, Alberte Bay Villekjaer Pedersen, Maximilian Keller,Caleb Webber, Helga E. de Vries,Olaf Ansorge,Christer Betsholtz,Marijke De Bock,Catarina Chaves,Birger Brodin,Morten S. Nielsen,Winfried Neuhaus,Robert D. Bell,Tamas Letoha,Axel H. Meyer,German Leparc,Martin Lenter,Dominique Lesuisse,Zameel M. Cader,Stephen T. Buckley,Irena Loryan,Claus U. Pietrzik
Cegarra Céline, Chaves C., Déon C.,Do T. M., Dumas B., Frenzel A., Kuhn P., Roudieres V., Guillemot J. C.,Lesuisse D.
Drug Delivery to the BrainAAPS Advances in the Pharmaceutical Sciences Seriespp.27-69, (2022)
Céline Cegarra,Catarina Chaves,Catherine Déon,Tuan Minh Do, Bruno Dumas, André Frenzel, Philip Kuhn,Valérie Roudieres,Jean-Claude Guillemot,Dominique Lesuisse
semanticscholar(2021)
Organic & medicinal chemistry international journalno. 3 (2021)
加载更多
作者统计
#Papers: 85
#Citation: 1856
H-Index: 24
G-Index: 38
Sociability: 6
Diversity: 2
Activity: 14
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn